Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington's Disease

被引:35
作者
Wood, Nigel I. [1 ]
Sawiak, Stephen J. [2 ,4 ]
Buonincontri, Guido [2 ]
Niu, Youguo [3 ]
Kane, Andrew D. [3 ]
Carpenter, T. Adrian [2 ]
Giussani, Dino A. [3 ]
Morton, A. Jennifer [1 ]
机构
[1] Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England
[2] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England
[3] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge, England
[4] Behav & Clin Neurosci Inst, Cambridge, England
基金
英国生物技术与生命科学研究理事会;
关键词
Huntington's disease; R6/2; mouse; cardiac dysfunction; MRI; Langendorff;
D O I
10.3233/JHD-2012-120004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
HD is a progressive genetic neurological disorder, characterized by motor as well as cognitive impairments. The gene carrying the mutation causing Huntington's disease (HD) is not brain specific, and there is increasing evidence for peripheral, as well as brain pathology in this disorder. Here, we used in vivo and ex vivo techniques to assess the cardiac function of mice transgenic for the HD mutation. Using magnetic resonance imaging (MRI) of the beating heart, we show that abnormalities previously reported in end-stage mice are present by mid-stages of the disease. We also found abnormalities that have not been hitherto reported, including changes in cardiac efficiency and a mechanical distortion of the beating heart. Using the Langendorff preparation, we show reduced coronary blood flow, impaired myocardial contractility and reduced left ventricular developed pressure inHDmouse hearts. Together, our findings suggest that there is significant pathology of theHDmouse heart, even by mid stages of disease. Previous clinical research has demonstrated that the risk of cognitive symptoms increases markedly in patients with heart failure. R6/2 mice show significant progressive cognitive abnormalities, so we hypothesize that cardiac pathology in the R6/2 mouse may contribute, not only to their progressive decline and death, but also to their cognitive dysfunction. We suggest that closer attention should be paid to cardiovascular symptoms in HD patients.
引用
收藏
页码:57 / 64
页数:8
相关论文
共 50 条
[21]   CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model [J].
Chou, SY ;
Lee, YC ;
Chen, HM ;
Chiang, MC ;
Lai, HL ;
Chang, HH ;
Wu, YC ;
Sun, CN ;
Chien, CL ;
Lin, YS ;
Wang, SC ;
Tung, YY ;
Chang, C ;
Chern, YJ .
JOURNAL OF NEUROCHEMISTRY, 2005, 93 (02) :310-320
[22]   Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease [J].
Zadori, Denes ;
Geisz, Andrea ;
Vamos, Eniko ;
Vecsei, Laszlo ;
Klivenyi, Peter .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2009, 94 (01) :148-153
[23]   Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model [J].
Mohammed, Abuelnor ;
Ramadan, Azza ;
Elnour, Asim Ahmed ;
Saeed, Ali Awadallah Ali Mohamed ;
Al Mazrouei, Nadia ;
Alsulami, Fahad T. ;
Alqarni, Yousef Saeed ;
Menon, Vineetha ;
Al Amoodi, Abdulla ;
Abdalla, Sami Fatehi .
CNS NEUROSCIENCE & THERAPEUTICS, 2024, 30 (09)
[24]   Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease [J].
Cepeda, C ;
Hurst, RS ;
Calvert, CR ;
Hernández-Echeagaray, E ;
Nguyen, OK ;
Jocoy, E ;
Christian, LJ ;
Ariano, MA ;
Levine, MS .
JOURNAL OF NEUROSCIENCE, 2003, 23 (03) :961-969
[25]   The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease [J].
Hickey, MA ;
Reynolds, GP ;
Morton, AJ .
JOURNAL OF NEUROCHEMISTRY, 2002, 81 (01) :46-59
[26]   Early Cognitive Dysfunction in the HD 51 CAG Transgenic Rat Model of Huntington's Disease [J].
Fink, Kyle D. ;
Rossignol, Julien ;
Crane, Andrew T. ;
Davis, Kendra K. ;
Bavar, Angela M. ;
Dekorver, Nicholas W. ;
Lowrance, Steven A. ;
Reilly, Mark P. ;
Sandstrom, Michael I. ;
von Hoersten, Stephan ;
Lescaudron, Laurent ;
Dunbar, Gary L. .
BEHAVIORAL NEUROSCIENCE, 2012, 126 (03) :479-487
[27]   Behaviour changes in a transgenic model of Huntington's disease [J].
Klivenyi, P ;
Bende, Z ;
Hartai, Z ;
Penke, Z ;
Nemeth, H ;
Toldi, J ;
Vecsei, L .
BEHAVIOURAL BRAIN RESEARCH, 2006, 169 (01) :137-141
[28]   Development of Hippocampus-Associated Cognitive Dysfunction in Huntington's Disease Mouse Model [J].
Kraskovskaya, N. A. ;
Erofeev, A. I. ;
Grishina, E. D. ;
Pushkareva, S. A. ;
Gerasimov, E. I. ;
Vlasova, O. L. ;
Bezprozvanny, I. B. .
JOURNAL OF EVOLUTIONARY BIOCHEMISTRY AND PHYSIOLOGY, 2021, 57 (06) :1449-1460
[29]   Development of Hippocampus-Associated Cognitive Dysfunction in Huntington’s Disease Mouse Model [J].
N. A. Kraskovskaya ;
A. I. Erofeev ;
E. D. Grishina ;
S. A. Pushkareva ;
E. I. Gerasimov ;
O. L. Vlasova ;
I. B. Bezprozvanny .
Journal of Evolutionary Biochemistry and Physiology, 2021, 57 :1449-1460
[30]   The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease [J].
Cuesta, Marc ;
Aungier, Juliet ;
Morton, A. Jennifer .
NEUROBIOLOGY OF DISEASE, 2012, 45 (01) :145-155